Can I read Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) on EtoBox?

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) by Shun Lu; Jie Wang; Ying Cheng; Tony Mok; Jianhua Chang; Li Zhang; Jifeng Feng; Hai-Yan Tu; Lin Wu; Yiping Zhang; Alexander Luft; Jian-ying Zhou; Zhiyong Ma; You Lu; Chengping Hu; Yuankai Shi; Kejing Ying; Hua Zhong; Elena Poddubskaya; Ross A Soo; Yee Hong Chia; Ang Li; Amy Li; Yi-Long Wu is a Medicine article available to read on EtoBox.

What is Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) about?

## Background: In the phase 3 checkmate 078 study, nivolumab showed significant overall survival (os) benefit and superior tolerability versus docetaxel in a predominantly chinese patient population with non-small cell lung cancer (nsclc). however, data on long-term outcomes with immunotherapy in asian patients are limited. we report 2-year efficacy and safety data. ## Methods: Patients with advanced/metastatic nsclc and disease progression after platinum-doublet chemotherapy were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks; n = 338) or docetaxel (75 mg/m every 3 weeks; n = 166) until progression, unacceptable toxicity, or other protocol-defined reasons. the primary endpoint was os; secondary endpoints included progression-free survival, objective response rate, and safety. ## Results: After 25.9 months minimum follow-up, 21 patients (6 %) remained on nivolumab versus 0 on docetaxel. median os was 11.9 months with nivolumab versus 9.5 months with docetaxel (hr: 0.75; 95 % ci: 0.61-0.93); 2-year os rates were 28 % versus 18 %, respectively. survival benefits were observed across a variety of predefined subgroups. at 2 years, 39 % and 0 % of responders had ongoing responses wi

Who reads Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)?

Author

Shun Lu; Jie Wang; Ying Cheng; Tony Mok; Jianhua Chang; Li Zhang; Jifeng Feng; Hai-Yan Tu; Lin Wu; Yiping Zhang; Alexander Luft; Jian-ying Zhou; Zhiyong Ma; You Lu; Chengping Hu; Yuankai Shi; Kejing Ying; Hua Zhong; Elena Poddubskaya; Ross A Soo; Yee Hong Chia; Ang Li; Amy Li; Yi-Long Wu

Publisher

Elsevier BV

Published

2020

Language

EN

Field

Medicine (Health Sciences)